Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: Association with tumor progression

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

1987 • 1,906 citations

The urokinase-type plasminogen activator system in cancer metastasis: A review

1997 • 1,561 citations

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

2002 • 592 citations

Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

2001 • 442 citations

Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.

1990 • 374 citations

Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.

2001 • 336 citations

Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes

1997 • 304 citations

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

1992 • 239 citations

Carcinoma of the ovary.

2001 • 198 citations

Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based Chemotherapy

1994 • 140 citations

Identification and cDNA Cloning of a Novel RNA-binding Protein That Interacts with the Cyclic Nucleotide-responsive Sequence in the Type-1 Plasminogen Activator Inhibitor mRNA

2001 • 135 citations

Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues

1999 • 135 citations

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

1999 • 130 citations

Plasmin/Plasminogen System in Colorectal Cancer

2002 • 121 citations

Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.

1994 • 107 citations

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

1995 • 96 citations

Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients

1998 • 95 citations

„IMO” - Intraoperatives Mapping des Ovarialkarzinoms

2003 • 89 citations

Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.

2001 • 82 citations

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

1996 • 68 citations

Operative Results after Primary and Secondary Debulking‐Operations in Advanced Ovarian Cancer (AOC)

1998 • 60 citations

Characterization of a new family of proteins that interact with the C‐terminal region of the chromatin‐remodeling factor CHD‐3¹

2002 • 54 citations

The plasminogen‐activation system in ovarian tumors

1993 • 53 citations

Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)

2001 • 45 citations

Posttranscriptional regulation of PAI-1 gene expression

2003 • 37 citations

Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer

2000 • 35 citations

Altered Expression Pattern of Topoisomerase IIα, in Ovarian Tumor Epithelial and Stromal Cells after Platinum-Based Chemotherapy

2006 • 29 citations

Urokinase and Plasminogen Activator-Inhibitor (PAI-1) Status in Primary Ovarian Carcinomas and Ovarian Metastases Compared to Benign Ovarian Tumors as A Function of Histopathological Parameters

1999 • 23 citations

Second-line treatment and consolidation therapies in advanced ovarian cancer

2001 • 22 citations

uPA und PAI-1 haben nicht nur eine prognostische, sondern auch eine prädiktive Bedeutung und unterstützen klinische Therapieentscheidungen beim primären Mammakarzinom

2003 • 6 citations

Cited By (0)

Loading...